Comparison of 3 Etest® methods and time-kill assay for determination of antimicrobial synergy against carbapenemase-producing Klebsiella species

Diagnostic Microbiology and Infectious Disease

Volumn 77, Issue 3, 2013, Pages 220-226

  Pankey, George A ^a   Ashcraft, Deborah S ^a   Dornelles, Adriana ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

Etest; Klebsiella; Synergy

Indexed keywords

MEROPENEM; POLYMYXIN B;

ARTICLE; ASSAY; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CONTROLLED STUDY; CROSS METHOD; DIRECT OVERLAY METHOD; DRUG POTENTIATION; INTERMETHOD COMPARISON; KLEBSIELLA PNEUMONIAE; MIC MIC METHOD; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAPID TEST; TEST STRIP; TIME KILL ASSAY;

ETEST; KLEBSIELLA; SYNERGY;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; DRUG SYNERGISM; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS;

EID: 84885390856     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2013.07.006     Document Type: Article

References (41)

1. ® antimicrobial susceptibility testing for in vitro diagnostic use: package insert instructions 2010, bioMérieux, Inc., Durham, NC.
2. Bonapace C.R., White R.L., Friedrich L.V., Bosso J.A. Evaluation of antibiotic synergy against Acinetobacter baumannii: a comparison with Etest, time-kill, and checkerboard methods. Diagn Microbiol Infect Dis 2000, 38:43-50.
3. Chachanidze V., Curbelo-Irizarry A., Ashcraft D., Pankey G. In vitro synergy of levofloxacin plus piperacillin-tazobactam against Pseudomonas aeruginosa. Interdis Perspect Infect Dis 2009, 10.1155/2009/984934.
4. Cilli F., Aydemir S., Tunger A. In vitro activity of daptomycin alone and in combination with various antimicrobials against gram-positive cocci. J Chemother 2006, 18:27-32.
5. Clinical and Laboratory Standards Institute (CLSI) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Ninth edition. M07-A9 2012, CLSI, Wayne, PA.
6. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing; Twenty-third informational supplement. M100-S23 2013, CLSI, Wayne, PA.
7. Eliopoulos G.M., Eliopoulos C.T. Antibiotic combinations: should they be tested?. Clin Microbiol Rev 1988, 1:139-156.
8. European Committee on Antimicrobial Susceptibility Testing (EUCAST) Breakpoint tables for interpretation of MICs and zone diameters. Version 3.0 Jan. 31, 2013. http://www.eucast.org.
9. Fleiss J. Statistical methods for rates and proportions 1981, Wiley, New York. 2nd ed.
10. Gordon N.C., Png K., Wareham D.W. Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother 2010, 54:5316-5322.
11. Guelfi K.C., Tognim M.C.B., Cardoso C.L., Gales A.C., Carrara-Marrone F.E., Garcia L.B. In vitro evaluation of the antimicrobial activity of meropenem in combination with polymyxin B and gatifloxacin against Pseudomonas aeruginosa and Acinetobacter baumanni. J Chemother 2008, 20:180-185.
12. Gülmez D., Çakar A., Şener B., Karakaya J., Hasçelik G. Comparison of different antimicrobial susceptibility testing methods for Stenotrophomonas maltophilia and results of synergy testing. J Infect Chemother 2010, 16:322-328.
13. Hellmark B., Unemo M., Nilsdotter-Augustinsson Å., Söderquist B. In vitro antimicrobial synergy testing of coagulase-negative staphylococci isolated from prosthetic joint infections using Etest and with a focus on rifampicin and linezolid. Eur J Clin Microbiol Infect Dis 2010, 29:591-595.
14. Jernigan M.G., Press E.G., Nguyen M.H., Clancy C.J., Shields R.K. The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2012, 56:3395-3398.
15. Kiratisin P., Apisarnthanarak A., Kaewdaeng S. Synergistic activities between carbapenems and other antimicrobial agents against Acinetobacter baumannii including multidrug-resistant and extensively drug-resistant isolates. Int J Antimicrob Agents 2010, 36:243-246.
16. Lat A., Clock S.A., Wu F., Whittier S., Della-Latta P., Fauntleroy K., et al. Comparison of polymyxin B, tigecycline, cefepime, and meropenem MICs for KPC-producing Klebsiella pneumoniae by broth microdilution, Vitek 2, and Etest. J Clin Microbiol 2011, 49(5):1795-1798.
17. Manno G., Ugolotti E., Belli M.L., Fenu M.L., Romano L., Cruciani M. Use of the Etest to assess synergy of antibiotic combinations against isolates of Burkholderia cepacia-complex from patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 2003, 22:28-34.
18. Mendes R.E., Kiyiota K.A., Monteiro J., Castanheira M., Andrade S.S., Gales A.C., et al. Rapid detection and identification of metallo-β-lactamase-encoding genes by multiplex real-time PCR assay and melt curve analysis. J Clin Microbiol 2007, 45:544-547.
19. Miyasaki Y., Morgan M.A., Chan R.C., Nichols W.S., Hujer K.M., Bonomo R.A., et al. In vitro activity of antibiotic combinations against multidrug-resistant strains of Acinetobacter baumannii and the effects of their antibiotic resistance determinants. FEMS Microbiol Lett 2012, 328:26-31.
20. Moody J. Synergism testing: broth microdilution checkerboard and broth macrodilution methods. Clinical Microbiology Procedures Handbook 2010, 5.12.1-5.12.23. American Society for Microbiology, Washington, DC. 3rd ed. L.S. Garcia (Ed.).
21. Moskowitz S.M., Garber E., Chen Y., Clock S.A., Tabibi S., Miller A.K., et al. Colistin susceptibility testing: evaluation of reliability for cystic fibrosis isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia. J Antimicrob Chemother 2010, 65:1416-1423.
22. National Committee for Clinical Laboratory Standards (NCCLS) Methods for determining bactericidal activity of antimicrobial agents; approved guideline. NCCLS document M26-A 1999, NCCLS, Wayne, PA.
23. Orhan G., Bayram A., Zer Y., Balci I. Synergy tests by Etest and checkerboard methods of antimicrobial combinations against Brucella melitensis. J Clin Microbiol 2005, 43:140-143.
24. Ozhak-Baysan B., Ongut G., Ogunc D., Gunseren F., Sepin-Ozen N., Ozturk F., et al. Evaluation of in vitro activities of tigecycline and various antibiotics against Brucella spp. Polish J Microbiol 2010, 59:55-60.
25. Pankey G.A., Ashcraft D.S. In vitro synergy of ciprofloxacin and gatifloxacin against ciprofloxacin-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005, 49:2959-2964.
26. Pankey G.A., Ashcraft D.S. The detection of synergy between meropenem and polymyxin B against meropenem-resistant Acinetobacter baumannii using Etest® and time-kill assay. Diagn Microbiol Infect Dis 2009, 63:228-232.
27. Pankey G.A., Ashcraft D.S. In vitro synergistic/additive activity of levofloxacin with meropenem against Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis 2010, 67:297-300.
28. Pankey G.A., Ashcraft D.S. Detection of synergy using the combination of polymyxin B with either meropenem or rifampin against carbapenemase-producing Klebsiella pneumoniae. Diagn Microbiol Infect Dis 2011, 70:561-564.
29. Pankey G., Ashcraft D., Patel N. In vitro synergy of daptomycin plus rifampin against Enterococcus faecium resistant to both linezolid and vancomycin. Antimicrob Agents Chemother 2005, 49:5166-5168.
30. Pillai S.K., Moellering R.C., Eliopoulos G.M. Antimicrobial combinations. Antibiotics in Laboratory Medicine 2005, 365-440. Lippincott Williams and Wilkins, Philadelphia, PA. 5th ed. V. Lorian (Ed.).
31. Qureshi Z.A., Paterson D.L., Potoski B.A., Kilayko M.C., Sandovsky G., Sordillo E., et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 2012, 56:2108-2113.
32. Rand K.H., Houck H. Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci. J Antimicrob Chemother 2004, 53:530-532.
33. Rasheed J.K., Biddle J.W., Anderson K.F., Washer L., Chenoweth C., Perrin J., et al. Detection of the Klebsiella pneumoniae carbapenemase type-2 carbapenem-hydrolyzing enzyme in clinical isolates of Citrobacter freundii and K. oxytoca carrying a common plasmid. J Clin Microbiol 2008, 46:2066-2069.
34. Sopirala M.M., Mangino J.E., Gebreyes W.A., Biller B., Bannerman T., Balada-Llasat J., et al. Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2010, 54:4678-4683.
35. Tan T.Y., Ng S.Y. Comparison of Etest, Vitek and agar dilution for susceptibility testing of colistin. Clin Microbiol Infect 2007, 13:541-544.
36. Tan T.Y., Ng L.S.Y., Tan E., Huang G. In vitro effect of minocycline and colistin combinations on imipenem-resistant Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 2007, 60:421-423.
37. Tan T.Y., Lim T.P., Lee W.H.L., Sasikal S., Hsu L.Y., Kwa A.L. In vitro antibiotic synergy in extensively drug-resistant Acinetobacter baumannii: the effect of testing by time-kill, checkerboard, and Etest methods. Antimicrob Agents Chemother 2011, 55:436-438.
38. Tsuji B.T., Rybak M.J. Etest synergy testing of clinical isolates of Staphylococcus aureus demonstrating heterogeneous resistance to vancomycin. Diagn Microb Infect Dis 2006, 54:73-77.
39. Wareham D.W., Bean D.C. In-vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases. Ann Clin Microbiol Antimicrob 2006, 5:10.
40. Wareham D.W., Gordon N.C., Hornsey M. In vitro activity of teicoplanin combined with colistin versus multidrug-resistant strains of Acinetobacter baumannii. J Antimicrob Chemother 2011, 66:1047-1051.
41. White R.L., Burgess D.S., Manduru M., Bosso J.A. Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and Etest. Antimicrob Agents Chemother 1996, 40:1914-1918.